Logo image of ILU.DE

ILLUMINA INC (ILU.DE) Stock Price, Forecast & Analysis

Europe - Frankfurt Stock Exchange - FRA:ILU - US4523271090 - Common Stock

107.46 EUR
+3.2 (+3.07%)
Last: 11/21/2025, 7:00:00 PM

ILU.DE Key Statistics, Chart & Performance

Key Statistics
Market Cap16.52B
Revenue(TTM)4.29B
Net Income(TTM)703.00M
Shares153.70M
Float153.39M
52 Week High143.78
52 Week Low62
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)3.78
PE28.43
Fwd PE24.48
Earnings (Next)02-04 2026-02-04/amc
IPO2000-06-28
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences


ILU.DE short term performance overview.The bars show the price performance of ILU.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 10 20 30 40 50

ILU.DE long term performance overview.The bars show the price performance of ILU.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -20 -40

The current stock price of ILU.DE is 107.46 EUR. In the past month the price increased by 23.35%. In the past year, price decreased by -19.97%.

ILLUMINA INC / ILU Daily stock chart

ILU.DE Competitors/Peers

The largest stocks on the EU markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
DIM.PA SARTORIUS STEDIM BIOTECH 44.08 18.49B
56S1.DE SARTORIUS STEDIM BIOTECH 43.97 18.44B
SRT3.DE SARTORIUS AG-VORZUG 49.3 16.83B
SRT.DE SARTORIUS AG 38.86 13.27B
QIA.DE QIAGEN N.V. 19.6 8.76B
1SXP.DE SCHOTT PHARMA AG& CO KGAA 19.01 2.78B
EVT.DE EVOTEC SE N/A 1.85B
GXI.DE GERRESHEIMER AG 6.38 813.76M
FF.MI FINE FOODS & PHARMACEUTICALS 10.13 198.98M

About ILU.DE

Company Profile

ILU logo image Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,970 full-time employees. The company went IPO on 2000-06-28. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.

Company Info

ILLUMINA INC

5200 Illumina Way

San Diego CALIFORNIA US

Employees: 9000

ILU Company Website

ILU Investor Relations

Phone: 18582024500

ILLUMINA INC / ILU.DE FAQ

What does ILLUMINA INC do?

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company is headquartered in San Diego, California and currently employs 8,970 full-time employees. The company went IPO on 2000-06-28. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.


What is the stock price of ILLUMINA INC today?

The current stock price of ILU.DE is 107.46 EUR. The price increased by 3.07% in the last trading session.


Does ILLUMINA INC pay dividends?

ILU.DE does not pay a dividend.


What is the ChartMill technical and fundamental rating of ILU stock?

ILU.DE has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.


How many employees does ILLUMINA INC have?

ILLUMINA INC (ILU.DE) currently has 9000 employees.


What is ILLUMINA INC worth?

ILLUMINA INC (ILU.DE) has a market capitalization of 16.52B EUR. This makes ILU.DE a Large Cap stock.


ILU.DE Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to ILU.DE. When comparing the yearly performance of all stocks, ILU.DE turns out to be only a medium performer in the overall market: it outperformed 45.12% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ILU.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to ILU.DE. ILU.DE has an excellent profitability rating, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ILU.DE Financial Highlights

Over the last trailing twelve months ILU.DE reported a non-GAAP Earnings per Share(EPS) of 3.78. The EPS increased by 152.02% compared to the year before.


Industry RankSector Rank
PM (TTM) 16.39%
ROA 11.38%
ROE 29.53%
Debt/Equity 0.42
Chartmill High Growth Momentum
EPS Q2Q%17.54%
Sales Q2Q%0.37%
EPS 1Y (TTM)152.02%
Revenue 1Y (TTM)-2.32%

ILU.DE Forecast & Estimates

28 analysts have analysed ILU.DE and the average price target is 103.69 EUR. This implies a price decrease of -3.51% is expected in the next year compared to the current price of 107.46.

For the next year, analysts expect an EPS growth of 93.48% and a revenue growth -1.07% for ILU.DE


Analysts
Analysts72.86
Price Target103.69 (-3.51%)
EPS Next Y93.48%
Revenue Next Year-1.07%

ILU.DE Ownership

Ownership
Inst Owners102.96%
Ins Owners0.18%
Short Float %N/A
Short RatioN/A